JP2021527039A5 - - Google Patents
Info
- Publication number
- JP2021527039A5 JP2021527039A5 JP2020567578A JP2020567578A JP2021527039A5 JP 2021527039 A5 JP2021527039 A5 JP 2021527039A5 JP 2020567578 A JP2020567578 A JP 2020567578A JP 2020567578 A JP2020567578 A JP 2020567578A JP 2021527039 A5 JP2021527039 A5 JP 2021527039A5
- Authority
- JP
- Japan
- Prior art keywords
- patent document
- document
- application publication
- prior
- patent application
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024056596A JP2024096738A (ja) | 2018-06-05 | 2024-03-29 | 悪性リンパ腫性障害の治療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862680739P | 2018-06-05 | 2018-06-05 | |
| US62/680,739 | 2018-06-05 | ||
| PCT/US2019/035576 WO2019236703A1 (en) | 2018-06-05 | 2019-06-05 | Methods of treating malignant lymphoproliferative disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024056596A Division JP2024096738A (ja) | 2018-06-05 | 2024-03-29 | 悪性リンパ腫性障害の治療法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021527039A JP2021527039A (ja) | 2021-10-11 |
| JP2021527039A5 true JP2021527039A5 (https=) | 2022-06-13 |
| JPWO2019236703A5 JPWO2019236703A5 (https=) | 2022-06-13 |
| JP7794564B2 JP7794564B2 (ja) | 2026-01-06 |
Family
ID=68769443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567578A Active JP7794564B2 (ja) | 2018-06-05 | 2019-06-05 | 悪性リンパ腫性障害の治療法 |
| JP2024056596A Pending JP2024096738A (ja) | 2018-06-05 | 2024-03-29 | 悪性リンパ腫性障害の治療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024056596A Pending JP2024096738A (ja) | 2018-06-05 | 2024-03-29 | 悪性リンパ腫性障害の治療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11510904B2 (https=) |
| EP (1) | EP3801768A4 (https=) |
| JP (2) | JP7794564B2 (https=) |
| KR (1) | KR20210045364A (https=) |
| CN (2) | CN112351819B (https=) |
| AU (1) | AU2019280693B2 (https=) |
| BR (1) | BR112020024931A2 (https=) |
| CA (1) | CA3102555A1 (https=) |
| IL (2) | IL279155B2 (https=) |
| MX (2) | MX2020013163A (https=) |
| WO (1) | WO2019236703A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112351819B (zh) * | 2018-06-05 | 2023-11-10 | 开动疗法公司 | 治疗恶性淋巴增生性疾病的方法 |
| AU2020415440A1 (en) * | 2019-12-26 | 2022-08-04 | Actuate Therapeutics, Inc. | Compounds for the treatment of myelofibrosis |
| WO2022109057A1 (en) * | 2020-11-17 | 2022-05-27 | Brown University | Inhibition of glycogen synthase kinase-3 (gsk-3) |
| JP2022157223A (ja) * | 2021-03-31 | 2022-10-14 | 国立大学法人神戸大学 | 抗ガン剤効果増強剤 |
| CN113684180B (zh) * | 2021-08-31 | 2023-05-26 | 山东大学第二医院 | 一种提高骨髓瘤杀伤活性的nk细胞制备方法 |
| WO2023172629A2 (en) * | 2022-03-08 | 2023-09-14 | Brown University | Anticancer maleimide derivatives for use with immune checkpoint blockade |
| US20250325517A1 (en) * | 2022-06-27 | 2025-10-23 | Actuate Therapeutics, Inc. | Oral dosage forms of elraglusib |
| US20260060969A1 (en) * | 2022-08-04 | 2026-03-05 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of lymphoproliferative disorders |
| WO2025245059A1 (en) * | 2024-05-23 | 2025-11-27 | Yale University | Compositions comprising gsk-3 and/or beta-catenin inhibitors and/or degraders and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2673368C (en) | 2006-12-19 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders |
| CA2860250C (en) | 2012-02-21 | 2020-11-10 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| JP6321662B2 (ja) | 2012-10-12 | 2018-05-09 | ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. | Ｇｓｋ３阻害剤およびその使用の方法 |
| US20160375006A1 (en) * | 2012-10-12 | 2016-12-29 | The Broad Institute, Inc. | Uses of paralog-selective inhibitors of gsk3 kinases |
| WO2014165851A1 (en) * | 2013-04-05 | 2014-10-09 | The Children's Hospital Of Philadelphia | Transient up-regulation of myc in b-cell lymphomas |
| US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| JP6534098B2 (ja) * | 2014-09-12 | 2019-06-26 | 国立大学法人 鹿児島大学 | 成人ｔ細胞白血病治療薬 |
| CN112351819B (zh) * | 2018-06-05 | 2023-11-10 | 开动疗法公司 | 治疗恶性淋巴增生性疾病的方法 |
-
2019
- 2019-06-05 CN CN201980037210.9A patent/CN112351819B/zh active Active
- 2019-06-05 WO PCT/US2019/035576 patent/WO2019236703A1/en not_active Ceased
- 2019-06-05 CN CN202311356900.5A patent/CN117883438A/zh active Pending
- 2019-06-05 US US15/734,699 patent/US11510904B2/en active Active
- 2019-06-05 BR BR112020024931-9A patent/BR112020024931A2/pt not_active Application Discontinuation
- 2019-06-05 IL IL279155A patent/IL279155B2/en unknown
- 2019-06-05 IL IL315565A patent/IL315565A/en unknown
- 2019-06-05 EP EP19815715.8A patent/EP3801768A4/en not_active Withdrawn
- 2019-06-05 AU AU2019280693A patent/AU2019280693B2/en active Active
- 2019-06-05 JP JP2020567578A patent/JP7794564B2/ja active Active
- 2019-06-05 CA CA3102555A patent/CA3102555A1/en active Pending
- 2019-06-05 KR KR1020207037918A patent/KR20210045364A/ko not_active Ceased
- 2019-06-05 MX MX2020013163A patent/MX2020013163A/es unknown
-
2020
- 2020-12-03 MX MX2024008461A patent/MX2024008461A/es unknown
-
2022
- 2022-11-03 US US18/052,369 patent/US11980607B2/en active Active
-
2024
- 2024-03-29 JP JP2024056596A patent/JP2024096738A/ja active Pending
- 2024-04-09 US US18/630,283 patent/US20240366563A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527039A5 (https=) | ||
| NO20080362L (no) | CD19-antistoffer og deres anvendelser | |
| Gao et al. | Human endogenous retroviruses in cancer: Expression, regulation and function | |
| MX374906B (es) | Nuevos inmunoconjugados | |
| NO20081987L (no) | Humane, monoklonale antistoffer mot CD70 | |
| MX2024002353A (es) | Celulas asesinas naturales modificadas geneticamente. | |
| JP2014087372A5 (https=) | ||
| EA201170492A1 (ru) | Векторы для генной терапии и цитозиндезаминазы | |
| JP2013517798A5 (https=) | ||
| PH12022553257A1 (en) | Antibodies to tigit | |
| JP2021524958A5 (https=) | ||
| FI2884999T4 (fi) | Menetelmä ja koostumuksia soluimmunoterapiaa varten | |
| NO20073797L (no) | Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA) | |
| Pei et al. | Current progress in EBV-associated B-cell lymphomas | |
| NO20064866L (no) | IRTA-5 antistoffer og deres anvendelse | |
| PH12018501291A1 (en) | Group b adenovirus encoding an anti-tcr-complex antibody or fragment | |
| MX354450B (es) | Anticuerpos anti proteína accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos. | |
| IN2014CN02518A (https=) | ||
| TW200745162A (en) | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 | |
| JP2014519854A5 (https=) | ||
| NO20083062L (no) | Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1 | |
| EA200602241A1 (ru) | Замещённые индазолы, композиции, содержащие указанные индазолы, способ их получения и применение | |
| EA200800229A1 (ru) | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) | |
| EA201790175A1 (ru) | Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований | |
| JP2018525453A5 (https=) |